title: Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes.
abstract: OBJECTIVE
  We compared the efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal. Primary efficacy parameter is the area under the curve (AUC) for postprandial plasma glucose.
  
  
  METHODS
  Miglitol was administered according to three different intake schedules in each subject: intake schedule A, no miglitol; intake schedule B, administration of miglitol (50 mg) just before breakfast; intake schedule C, dissolving miglitol (50 mg) in water and taking it just before (1/3), during (1/3), and just after breakfast (1/3). Blood samples were collected at 0, 30, 60, 120, and 180 min after breakfast.
  
  
  RESULTS
  The AUCs for plasma glucose, insulin, and total glucose-dependent insulinotropic polypeptide (GIP) were significantly lower for intake schedules B and C, compared with those for intake schedule A. The AUC for total glucagon like peptide-1(GLP-1) was higher for intake schedule C than for intake schedule A. The coefficient of variation (CV) of plasma glucose was significantly lower for intake schedule C than for intake schedules A and B.
  
  
  CONCLUSIONS
  Taking miglitol dissolved in water was equivalent to taking a miglitol tablet. The CV of plasma glucose was significantly lower for the dissolved-dose regimen.
authors.affiliation: a Department of Endocrinology and Metabolism , Yokohama City University Graduate School of Medicine , Yokohama , Japan.
authors.forename: Eriko
authors.initials: E
authors.lastname: Shibata
authors.affiliation: a Department of Endocrinology and Metabolism , Yokohama City University Graduate School of Medicine , Yokohama , Japan.|b Department of Biostatistics , Yokohama City University Hospital , Yokohama , Japan.
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Aoki
authors.affiliation: a Department of Endocrinology and Metabolism , Yokohama City University Graduate School of Medicine , Yokohama , Japan.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Tajima
authors.affiliation: b Department of Biostatistics , Yokohama City University Hospital , Yokohama , Japan.
authors.forename: Masataka
authors.initials: M
authors.lastname: Taguri
authors.affiliation: a Department of Endocrinology and Metabolism , Yokohama City University Graduate School of Medicine , Yokohama , Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Terauchi
mesh_terms: D017485:1-Deoxynojirimycin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D001786:Blood Glucose / Q000032:analysis; D062408:Breakfast; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period; D013607:Tablets
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D013607:Tablets; C045621:miglitol; D017485:1-Deoxynojirimycin; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1
keywords: Miglitol; liquid formulation; postprandial glucose; tablet formulation; type 2 diabetes